Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study)

Purpose. An expanded access program (PRIDE study) in Italy to provide ranibizumab 0.5 mg to diabetic macular edema (DME) patients, prior to reimbursement. Methods. Open-label, prospective, phase IIIb study. Majority of patients were not treatment-naïve before enrollment. Patients received ranibizuma...

詳細記述

保存先:
書誌詳細
出版年:J Ophthalmol
主要な著者: Menchini, Ugo, Bandello, Francesco, De Angelis, Vincenzo, Ricci, Federico, Bonavia, Luigi, Viola, Francesco, Muscianisi, Elisa, Nicolò, Massimo
フォーマット: Artigo
言語:Inglês
出版事項: Hindawi Publishing Corporation 2015
主題:
Clinical Study
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4532943/
https://ncbi.nlm.nih.gov/pubmed/26294963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/324841
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料